

20. ELN Symposium with 23. KNL Symposium

Congress Center Rosengarten, Mannheim, April 9, 2024, 8:00-20:00

WP sessions 1-4 (Mahler 1)

Chairs/Contributors

8:00 - 9:30

Session 1: WP5 AML 1

C. Röllig, G. Huls

- 30' Update RESOLVE EU Project
- 30' Update IMPACT EU Project
- 15' ELN Position Paper on Fitness in AML
- 15' Open forum for discussion and future projects

M. Heuser
G. Marconi
A. Venditti
All

9:30 - 9:45

Coffee Break

9:45 - 11:15

Session 2: WP5 AML 2 (Emerging therapies)

C. Röllig, G. Huls

Update European Academic AML trials and Registries

- 10' PETHEMA
- 10' PALG
- 10' ALFA
- 10' FILO
- 10' NCRI
- 10' GIMEMA
- 10' HOVON-AMLSG
- 10' SAL-AML CG
- 10' Discussion on joint future projects

P. Montesinos
A. Wierzbowska
H. Dombret
C. Recher
C. Craddock
A. Venditti
G. Ossenkoppele
C. Röllig
All

11:15 - 11:30

Break

11:30 - 13:00

Session 3: HARMONY Alliance Foundation

J.M. Hernandez, L. Bullinger

- 15' Established operational model and tools for clinicians & researchers
- 40' Progress of the AML Research Projects
- 25' Progress of the ALL, MDS, and CML Projects
- 5' The HARMONY Foundation – next steps

TBC
TBC
TBC
TBC

13:00 - 14:00

Lunch

14:00 - 15:30

Session 4: WP8 MDS

L. Malcovati, M. Mittelman

WP sessions 5-8 (Mahler 2)

Chairs/Contributors

8:00 - 9:30

Session 8: WP17 Biometry and Epidemiology

M. Pfirrmann, M. Lauseker

- 20' Multiple imputation
- 20' Endpoints / estimands when the PH assumption does not hold
- 20' Safety first: Strategies against biased analysis of adverse event data
- 20' interpreting the EURO-SKI study and its TFR outcome
- 10' Questions and answers

M. Lauseker
I. Azzali
T. Lang
M. Pfirrmann

9:30 - 9:45

Coffee Break

9:45 - 11:15

Session 6: WP4 CML

L. Stenke, A. Hochhaus

- 15' Life expectancy of Swedish CML patients

E. Yi-Tung

15'	QoL analyses for CML patients at baseline, nilotinib vs nilo + peg-IFN	M. Lorch
15'	Prediction of response to asciminib according to BCR::ABL1 mutations and variants. An EUTOS project.	O. Hantschel
15'	Validation of risk scores for pediatric CML patients	F. Millot
15'	Dasatinib holidays for improved tolerability: Final analysis of the DasaHit study	A. Hochhaus
15'	ELN recommendations for treating CML 2024	J. Apperley
11:15 - 11:30 Break		
11:30 - 13:00	Session 7: WP9 MPN	T. Barbui, M. Griesshammer
10'+5'	Non canonical variants in MPN: friend or foe? MPN-OLIVETTI registry	G. Carreño
10'+5'	Developing novel composite endpoints for myelofibrosis trials: the DEMYO –ELN project	M. Marchetti
10'+5'	BCR/ABL negative MPN in pregnancy, ELN Recommendations	M. Griesshammer
10'+5'	ELN registry in myelofibrosis “ERNEST-3”	T. Barbui
10'+5'	MPL-mutant and triple-negative essential thrombocythemia – a collaborative ELN project	S. Koschmieder
10'+5'	- Titel to follow -	D. Royston
13:00 - 14:00 Lunch		
14:00 - 15:30	Session 9: WP14 Transplantation	D. Niederwieser, W. Jędrzejczak, T. Ruutu
Completed projects		
5'	Oral at EBMT: Randomized study in elderly AML, HCT vs. CT	D. Niederwieser
5'	Global transplant registry: a center and internet-based survey of cellular therapies with more than 800.000 reports	D. Neumann
5'	Help for Ukrainian hematology patients – a global initiative supporting the establishment of hematology centers and HCT programs in a time of war	I. Korenks
Current projects		
5'	Waustim maintenance lenalidomide results	L. Gardaret
10'	Substudies of the Waustim project	L. Gardaret
5'	Developments in the clinical assessment of VOD/SOS	T. Ruutu
10'	Global transplant survey up to 2018 (manuscript)	Y. Atsuta
5'	R/R AML: HCT protocols	G. Marconi
10'	GvHD app	D. Neumann
5'	ELN Recommendations for treating CML	D. Niederwieser
New projects		
5'	Worldwide utilization of HCT in CML + outcome registry	all
5'	Worldwide utilization of AML outcome registry	all
10'	Al; GvHD recommendations	all
5'	Pediatric registry	all
WP sessions 9-12 (Mahler 3)		Chairs/Contributors
8:00 - 9:30	Session 5: WP6 ALL	S. Chiaretti, D. Hoelzer
10'	Combination of optimal genomic mapping (OGM) and NGS to improve the diagnosis of patients with B-other ALL	J.-M. Hernandez-Rivas
10'	Interaction between optical genomic mapping and digital Multiplex ligation-dependent probe amplification (MLPA)	G. La Pietra
10'	Long-term follow up of the PONALFIL Trial for adult patients with de no Ph+ALL	J.-M. Ribera

10'	Can we stop TKI Treatment in Ph+ ALL?	M. Dragani
10'	Developmental trajectories and cooperation genomic events define molecular subtypes of BCR::ABL1-positive ALL	T. Beder
10'	GMALL BOLD (Sequential Dose Reduced Chemotherapy and Blinatumomab) trial	N. Gökbüget
10'	Ponatinib for R/R Ph-like ALL: results from a compassionate use program	F. Kaiser
10'	2023 ELN Recommendations for ALL in adults: Diagnosis, Prognostic Factors and Assessment. Management	N. Gökbüget

9:30 - 9:45 Coffee Break

9.45 – 11.15 Session 10: WP10 Immunophenotyping

M.C. Béné, G. Zini

Morphology

- Update on AML NOS
- Digital morphology for bone marrow aspirates

G. Zini

G. Zini

Flow cytometry

- Update on MPAL
- Immunophenotypic changes after B-cell targeted therapies (bispecifics and CAR T-cells)

M.C. Béné

A. Dunlop

Break

11:30 - 13:00 Session 11: WP11 Cytogenetics

I. Summerer, B. Espinet

18'	Optical Genome Mapping in AML and B-ALL diagnosis	K. Rack
18'	The role of cytogenetics in precursor lesions (CHIP, CCUS)	G. Hörmann
18'	Utility of peripheral blood for mutational analysis in patients with confirmed or suspected MDS	S. Huber
18'	Cytogenetically visible and invisible fusion genes in MLN-TK	G. Metzgeroth
18'	Update on the use of AI in chromosome banding analysis	I. Summerer

13:00 - 14:00 Lunch

14:00 - 15:30 Session 12: WP12/13 MRD/NGS

M. Heuser, C. Thiede, T. Haferlach

How we define and clinically use MRD in hematologic malignancies

10'+5'	AML	M. Heuser
10'+5'	ALL	M. Brüggemann
10'+5'	CLL	A. Rawstron (pending)
10'+5'	CML	A. Hochhaus
10'+5'	MM	M.-V. Mateos (pending)
10'+5'	Clinical Trials	P. Ramos (pending)

13:00 – 14:00 Luncheon poster walk (Foyer)

R. Gale

Plenary Sessions (Mahler1)

16:00 - 17:30 Session 14: General Assembly and Summary reports

R. Hehlmann, D. Niederwieser

30'	General Assembly	R. Hehlmann
5'	WP5 (AML 1)	G. Huls TBC
5'	WP5 (AML 2)	C. Röllig
5'	HARMONY	J. Hernandez
5'	WP8 (MDS)	L. Malcovati
5'	WP17 (Statistics)	M. Pfirrmann
5'	WP4 (CML)	A. Hochhaus
5'	WP9 (MPN)	T. Barbui
5'	WP14 (Transplantation)	D. Niederwieser
5'	WP6 (ALL)	D. Hoelzer
5'	WP10 (Immunophenotyping)	M. Béné
5'	WP11 (Cytogenetics)	I. Summerer

5'	WP12/13 (MRD, NGS)	M. Heuser TBC
17:30-17:45	ELN Merit Awards/KNL Verdienstzertifikate	Introducer
	Derek MacLennan Nicola Gökbuget Stephan Pichl	G. Ossenkoppele D. Hoelzer R. Hehlmann
17:45 - 18:00	Break with Group photo	
18:00 - 20:00	Session 15: Keynote lectures	R. Hehlmann, D. Hoelzer
20'	ELN Laboratory Recommendations for managing CML	S. Soverini
20'	HARMONY dashboard for hematologic malignancies	A. Hernandez
20'	20 years cooperative research on MPNs in ELN-WP9	T. Barbui
20'	ELN recommendations on infections in leukemias	P. Ljungman
20'	25 years cooperative research on ALL within KNL and ELN-WP6	D. Hoelzer
20'	20 years AML in ELN WP5: was it worthwhile?	G. Ossenkoppele
20:00	Working dinner in the foyer	

